Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to ARHGAP39" (ENSG00000255456) is a long non-coding RNA identified as transcribed from the antisense strand at the ARHGAP39 locus[4]. No evidence suggests that this antisense transcript encodes a protein or functions as a therapeutic target (e.g., receptor, enzyme, transporter). Its potential biological role may involve regulation of ARHGAP39 expression via mechanisms such as chromatin modification or transcriptional interference, general to antisense RNAs[2]. ARHGAP39 itself (sense gene) is a Rho GTPase-activating protein involved in cell migration, apoptosis, and neural development, and is an emerging target in cancer therapy[1][3][5]; however, the antisense transcript’s function, clinical relevance, or druggability have not been established in the literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ARHGAP39 (ENSG00000255456).